Patients with Parkinson disease experiencing “off” episodes on levodopa/carbidopa now have another treatment option.
There is now another option for patients with Parkinson disease. The FDA has approved Xadago (safinamide) tablets as an add-on treatment for patients taking levodopa/carbidopa.
In patients experiencing “off” episodes, safinamide has been shown in two clinical trials to be efficacious in reducing involuntary movement and improving motor function scores.
The most common side effects are falls, nausea, insomnia, and dyskinesia.
